Dr Reddy’s Laboratories has decided to buy select established brands of Belgium-based UCB in India for 118 million euros (Rs 800 crore) as it looks to strengthen its presence in the dermatology, respiratory and paediatric segments. The company has entered into an agreement to acquire the portfolio of established products of UCB, in India, Nepal, Sri Lanka and Maldives.

“The acquired business is being sold on a slump sale basis. The transaction includes approximately 350 employees engaged in India operations. The revenues of the acquired business is approximately Rs 150 crore for calendar year 2014,’’ the company said.

Lawsuit settled, Sun arm can launch anti-coagulant in US

Sun Pharma has informed the BSE in a filing that the company and some of its subsidiaries have executed an agreement with The Medicines Company, USA, settling a US lawsuit against them. “Under the terms of agreement, the company’s subsidiary is entitled to launch its version of generic Angiomax (an anti-coagulant) in the US on June 30, 2019 or earlier under certain limited circumstances”, Sun Pharma said.